2Anonymous. New antimicrobial agents approved by the U. S. Food and Drug Administration in 2001 and new indications for previously approved agents[J]. Antimicrob Agents Chemother, 2002,46(3) : 1160. 被引量：1
3Walsh TJ, Tepper H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia[J]. N Engl J Med,2004,351(14) :1391-1402. 被引量：1
2Stevens DA,Kan VL,Judson MA,et al.Practice guidelines for diseases caused by Aspergillus.Infectious Diseases Society of America.Clin Infect Dis,2000,30:696-709. 被引量：1
3Ascioglu S,Rex JH,de Pauw B,et al.Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants:an international consensus.Clin Infect Dis,2002,34:7-14. 被引量：1
4Denning DW,Kibbler CC,Barnes RA,et al.British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections.Lancet Infect Dis,2003,3:230-240. 被引量：1
5Pappas PG,Rex JH,Sobel JD,et al.Guidelines for treatment of candidiasis.Clin Infect Dis,2004,38:161-189. 被引量：1
6Slavin MA,Szer J,Grigg AP,et al.Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections.Intern Med J,2004,34:192-200. 被引量：1
7Saag MS,Graybill RJ,Larsen RA,et al.Practice guidelines for the management of cryptococcal disease.Infectious Diseases Society of America.Clin Infect Dis,2000,30:710-718. 被引量：1
